Zobrazeno 1 - 10
of 562
pro vyhledávání: '"Hughes TP"'
Autor:
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, IRIS Investigators, IRIS Investigators.
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::1e9f79cd3dc87bed721a6a006c82818e
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1768
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1768
Autor:
Cullis, JO, Szydlo, RM, Cross, NC, Marks, DI, Schwarer, AP, Hughes, TP, Mackinnon, S, Hale, G, Waldmann, H, Hows, JM
Between January 1985 and March 1992, 48 patients with chronic phase CML underwent BMT from volunteer unrelated donors (MUD) serologically identical at HLA-A, B and DR loci. 19 patients received donor marrow ex vivo T-cell depleted (EX-TCD) with Campa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::660f6a0fdfcab3cd4ba28f563c0114a8
https://ora.ox.ac.uk/objects/uuid:eb88b41c-4cb5-4f1b-b813-b17b475d4756
https://ora.ox.ac.uk/objects/uuid:eb88b41c-4cb5-4f1b-b813-b17b475d4756
Autor:
Shah, Neil Pravin, le, PD, Hughes, TP, Mahon, F-X, Kim, D-W, Steegmann, JL, Shah, NP, Gooden, K, Wallis, N, Cortes, JE
Publikováno v:
Shah, Neil Pravin; le, PD; Hughes, TP; Mahon, F-X; Kim, D-W; Steegmann, JL; et al.(2016). Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/203260c2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::ba8221d5e8f29f25e631d2f8c3845127
http://www.escholarship.org/uc/item/203260c2
http://www.escholarship.org/uc/item/203260c2
Autor:
Cortes, JE, Pinilla-Ibarz, J, Le Coutre, PD, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, Baccarani, M, Lustgarten, S, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, TP, Shah, NP, Kantarjian, HM
Publikováno v:
21st Congress of the European Hematology Association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::a19a096480f8c3953e7ffeccf0d9d2ed
http://hdl.handle.net/10044/1/40379
http://hdl.handle.net/10044/1/40379
Autor:
Saglio, G, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Alimena, Giuliana, Larson, Ra, Kantarjian, Hm, Enestnd, Investigators
Publikováno v:
New England Journal of Medicine. 362:2251-2259
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome–positive chronic myel
Autor:
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson Ansah A, Legros L, Harousseau JL, Rigal Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde Dahl T, Hjorth Hansen H, Jedrzejczak W, Dmoszynska A, Starzak Dwozdz J, Holowiecki J, Kyrcz Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent D.J., PANE, FABRIZIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3730::dea15626236025aa3b59ad57f14b3d2a
http://hdl.handle.net/11588/371601
http://hdl.handle.net/11588/371601
Autor:
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, [in the IRIS Investigators, MARTINELLI, GIOVANNI
Publikováno v:
Leukemia. 23(6)
Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously unt
Autor:
Hochhaus A, Kantarjian HM, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah N.P., BACCARANI, MICHELE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::44cb2692482bf7a10574c8b3a47dfe72
http://hdl.handle.net/11585/56309
http://hdl.handle.net/11585/56309
Autor:
Saglio, Giuseppe, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, Ra, Kantarjian, Hm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______970::43b22ca62b07e3ca0a62be2c94081787
http://hdl.handle.net/2318/102212
http://hdl.handle.net/2318/102212